ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Correlation analysis of gut microbiota and metabolites in gastric cancer patients in plateau areas based on multi-omics technologies.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo characterize gut microbiota alterations and metabolic changes in gastric cancer (GC) patients from high-altitude regions using 16S rDNA sequencing and untargeted metabolomics.
methodsFecal samples from 30 GC patients and 30 healthy controls in Qinghai Province were analyzed. Microbial diversity and composition were assessed via 16S rDNA sequencing, and metabolite profiles were determined using untargeted metabolomics. Correlations between significantly altered microbial taxa and metabolites were evaluated.
resultsMicrobial diversity differed significantly between groups (P < 0.001). Proteobacteria abundance was higher in GC patients (P < 0.05). At the genus level, Prevotella_9, Streptococcus, and Lactobacillus showed significant differences (P < 0.05-P < 0.001). GC patients exhibited upregulation of desulfo-biotin, glycylproline, glycine, hydroxyhexanoic acid, tyramine, methanethiol oxidase, 5-aminopentanoic acid, citrulline, betaine, and formyl glutamic acid, and downregulation of cytidine, 5'-methylthioadenosine, trehalose, melezitose, lotaustralin, adenosine, creatinine, 5-methyluridine, raffinose, and galactitol. Proteobacteria correlated positively with desulfo-biotin, glycylproline, and glycine, while Lactobacillus correlated with several upregulated metabolites including tyramine and betaine (all P < 0.05). Cytidine correlated negatively with Proteobacteria, whereas creatinine and 5-methyluridine correlated positively with Prevotella_9.
conclusionGC patients in high-altitude regions display distinct gut microbiota and metabolite profiles, with notable microbe-metabolite associations. These findings suggest potential biomarkers and therapeutic targets for GC in plateau populations.
Indexed as
Identifiers
41615647What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.